Opinion|Videos|September 16, 2024
The Link Between Obesity and CRM Conditions
Key Takeaways
- Obesity management is crucial in patient-centered care for cardiometabolic conditions, affecting disease progression and treatment outcomes.
- Challenges in managing CRM conditions in obese patients include medication dosing, comorbidities, and lifestyle modification adherence.
Experts in the field of cardiometabolic risk management analyze the link between obesity and cardiometabolic conditions, outlining challenges and proposing potential solutions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the management of obesity factor into the patient centered care for patients with these CRM conditions?
- Are there any specific challenges in managing CRM conditions in patients with obesity? How can these challenges be addressed?
- What specific strategies have you implemented to both prevent and treat the complex disease of obesity?
- Can you share any success stories or case studies where weight management interventions have led to improvements in CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5